NextCell Pharma (NXTCL.ST) Stock Analysis & AI Equity Report
NextCell Pharma (NXTCL.ST) overview
NextCell Pharma (NXTCL.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, NextCell Pharma reported revenue of SEK 10.9m and operating profit of SEK -35.9m; the year-end share price was 1.17 SEK and market capitalisation was SEK 89.4m. NextCell Pharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get NextCell Pharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About NextCell Pharma
NextCell Pharma AB is a Swedish biopharmaceutical company focused on cell therapies and advanced therapy medicinal products. Its main businesses are ProTrans, a stromal cell therapy in development for autoimmune and inflammatory diseases, Cellaviva, a private stem cell bank, and QVance, which provides analytical services for advanced therapies.
Generate the NextCell Pharma report
NextCell Pharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for NextCell Pharma and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.